Shield Therapeutics (STU:1JS) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


What is Shield Therapeutics Forward Dividend Yield %?

Shield Therapeutics STU:1JS -2.16% Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. The stock has 5 warning signs investors should review. Among 504 Drug Manufacturers companies, Shield Therapeutics ranks worse than 198412.5% on this metric.

As of today (2026-06-25), the Forward Annual Dividend Yield of Shield Therapeutics is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of Shield Therapeutics is 0.00%.

STU:1JS's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.095
* Ranked among companies with meaningful Forward Dividend Yield % only.

Shield Therapeutics's Dividends per Share for the six months ended in Dec. 2025 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Shield Therapeutics  (STU:1JS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Shield Therapeutics Forward Dividend Yield % Related Terms

STU:1JS vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Forward Dividend Yield % falls into.


Shield Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Shield Therapeutics (STU:1JS) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #999999 out of 504 companies in the Drug Manufacturers industry.
Is Shield Therapeutics' Forward Dividend Yield % too high?
Shield Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Shield Therapeutics ranks #999999 out of 504 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #999999 out of 504 companies for Forward Dividend Yield %. This places Shield Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 2.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.10, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.09, compared to a current price of €0.07 — trading 24.4% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.